Skip to main content

SLAS2022 Main banner

Tweets by SLAS2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

ViewAttendees 4

On-demand recording will be available 24hrs after the presentation.

New Modalities

Advances in Antibody–Drug Conjugates

Tuesday, February 8, 2022

4:00 PM – 5:30 PM

Location: 206AB

Session Chair - Not Funded(s)

NM

Naniye Malli Cetinbas, PhD

Associate Director
Mersana Therapeutics, Massachusetts, United States

Presentations:

4:00 PM – 4:30 PM

Transitioning from Drug Screening to Drug Design for Next Generation Antibody Drug Conjugates
Greg Thurber, PhD – University of Michigan
4:30 PM – 5:00 PM

Site-specific Dolasynthen ADCs: A platform to generate a wide range of drug-to-antibody ratios and maintain consistent exposure
Kalli Catcott, PhD – Mersana Therapeutics